Valrubicin
Topoisomerase Inhibitor
DB00385
Approved Indication
For the treatment of cancer of the bladder.
1
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II.
Details
DrugBank ID
DB00385 ↗
Approval Date
1998-10-01
Molecular Weight
723.651 g/mol
Drug Class
Topoisomerase Inhibitor
ATC Codes
L01DB09
Synonyms
Valrubicin, Valrubicina, Valrubicine
PubChem
CID: 454216 ↗
ChEMBL
CHEMBL1096885 ↗
SMILES
[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1
ADMET Profile
Computing properties…